Trachoma and sexually transmitted diseases caused by Chlamydia trachomatis are major health problems worldwide. Epitopes on the major outer membrane protein (MOMP) of C. trachomatis have been identified as important targets for the development of vaccines. In order to examine the immunogenicity of a recombinant vector expressing a chlamydial epitope, a poliovirus hybrid was constructed in which part of neutralization antigenic site I of poliovirus type 1 Mahoney (PV1-M) was replaced by a sequence from variable domain I of the MOMP of C. trachomatis serovar A. The chlamydial sequence included the neutralization epitope VAGLEK. This hybrid was viable, grew very well compared with PV1-M, and expressed both poliovirus and chlamydial antigenic determinants. When inoculated into rabbits, this hybrid was highly immunogenic, inducing a strong response against both PV1-M and C. trachomatis serovar A. Antichlamydia titers were 10-to 100-fold higher than the titers induced by equimolar amounts of either purified MOMP or a synthetic peptide expressing the VAGLEK epitope. Furthermore, rabbit antisera raised against this hybrid neutralized chlamydial infectivity both in vitro, for hamster kidney cells, and passively in vivo, for conjunctival epithelia of cynomolgus monkeys. Because poliovirus infection induces a strong mucosal immune response in primates and humans, these results indicate that poliovirus-chlamydia hybrids could become powerful tools for the study of mucosal immunity to chlamydial infection and for the development of recombinant chlamydial vaccines.
Chlamydia trachomatis infects the epithelia of the conjunctivae and of the genital tract, causing trachoma and a variety of sexually transmitted diseases which can lead to blindness and infertility, respectively (36, 37) . There are 15 serovars of C. trachomatis; serovars A, B, and C are the causative agents of trachoma (10) , while serovars D, E, F, G, H, I, J, and K are the most common causative agents of chlamydial sexually transmitted diseases (36, 37) . Trachoma is the leading cause of preventable blindness in developing nations, and it is estimated that 500 million people suffer from trachoma, with as many as 7 million blinded by the disease (10) .
The pathogenesis of trachoma involves repeated ocular infections and the generation of a deleterious hypersensitivity response to chlamydial antigen(s) (19, 20, 41, 42) . The available evidence supports the hypothesis that secretory immunoglobulin A (IgA) is an important component of protection. In a primate model, ocular infection induces relatively rapid and persistent production of IgA in tears, whereas the presence of IgG in tears is transient, corresponding to the period of peak conjunctival inflammation and follicle formation (7) . Protective immunity against chlamydial ocular infection in a subhuman primate model is homotypic, and resistance to ocular challenge is correlated with the presence of serovar-specific antibodies in tears (18, 46) . Tears from infected humans neutralized the infectivity of homologous but not heterologous C. trachomatis serovars in owl monkey eyes (30) , whereas passive humoral immunization with antitrachoma antibodies was not protective (32) .
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Past attempts to develop whole-cell vaccines against trachoma have actually potentiated disease by sensitizing vaccinees (17, 19) . Thus, an effective trachoma vaccine will probably have to be based on a subunit immunogen capable of inducing a strong and enduring mucosal neutralizing antibody response without sensitizing the vaccinee.
The most promising candidate antigen for the development of a subunit vaccine is the chlamydial major outer membrane protein (MOMP) (6) . Other outer membrane proteins and the surface-exposed lipopolysaccharide are also highly immunogenic, but unlike the MOMP, antibodies to these antigens have not been shown to neutralize infectivity (51) . The MOMP, which is the predominant surface protein, is an integral membrane protein with a mass of ca. 40 kDa and, with the exception of four variable domains (VDs), is highly conserved among serovars. The sequences of the four VDs have been determined for all 15 serovars (49) . Antibodies capable of neutralizing chlamydial infectivity recognize the MOMP (24, 33, 40, 50, 51) . The binding sites of MOMPspecific neutralizing monoclonal antibodies have been mapped for serovars A, B, and C (2, 8, 25, 38, 50, 51) and represent important targets for the development of synthetic or subunit vaccines. These sites are contiguous sequences of six to eight amino acids located within VDI or VDII (depending on the serovar) and VDIV.
Synthetic peptides containing epitopes recognized by neutralizing antibodies can induce neutralizing antibodies of the desired specificity (39) , but immunization with these peptides by conventional means failed to induce mucosal immunity. Similarly, conventional immunization with MOMP would not be expected to induce significant mucosal immunity. It may, however, be possible to induce protective mucosal neutralizing antibodies against these epitopes by expressing them on poliovirus, which is known to efficiently induce a long-lasting mucosal immune response following infection of the gut (12, 13, 31) . A number of heterologous epitopes have been successfully expressed on poliovirus (5, 28 [and references therein], 29). These epitopes are generally short, well-defined, contiguous epitopes, and most have been expressed within poliovirus neutralization antigenic site I (NAgI). This site, of which there are 60 copies per virion, includes the loop linking beta strands B and C (the BC loop) of poliovirus capsid protein VP1 (21) . The BC loop is a surface-exposed loop of 9 amino acids (21) which can be replaced by at least 25 heterologous amino acids (27) . The MOMP epitopes therefore seem to be ideal for expression on poliovirus, and hybrid polioviruses expressing chlamydial neutralization epitopes appear particularly attractive for use as experimental tools and even as potential vaccines.
In order to determine the feasibility of constructing useful poliovirus-chlamydia hybrids and to assess their immunogenicity, we have constructed a poliovirus hybrid expressing the well-characterized VAGLEK neutralization epitope (39, 50, 51) from VDI of C. trachomatis serovar A MOMP. This hybrid grows nearly as well as wild-type poliovirus and expresses a functional chlamydial epitope. Furthermore, in terms of the ability to induce a humoral immune response in rabbits, this hybrid is highly immunogenic compared with chlamydia-specific synthetic peptides or purified MOMP.
MATERIALS AND METHODS
Hybrid polioviruses. Hybrid polioviruses were constructed by the mutagenesis cartridge strategy developed by Murray et al. (29) . Synthetic oligonucleotides coding for amino acids from VDI of the C. trachomatis serovar A MOMP were cloned into a full-length cDNA of poliovirus type 1 Mahoney strain (PV1-M) in place of sequences coding for some or all of PV1-M amino acids 1094 to 1102 (Fig. 1) . Note that we use the four-digit code for poliovirus amino acids; thus 1095 is amino acid 95 of capsid protein VP1, for example. Various combinations of poliovirus-and chlamydia-specific amino acids wete examined for their effects on viral growth and immunogenicity.
Transfection of Vero cells with RNA transcripts (45) of hybrid cDNAs yielded three hybrid viruses, designated PV1-CtS, -Ct7, and -Ct8. Transcripts of cDNAs pT7Ct2 and pT7Ct4 were apparently noninfectious. Transfection with transcripts of the parental PV1-M cDNA (pT7XLD) (28) yielded a transfection-derived wild-type poliovirus designated PV1-XLD. The identities of PV1-Ct7, PV1-Ct8, and PV1-XLD were confirmed by sequencing the virion RNA through the region coding for the inserted amino acids.
Chlamydiae. C. trachomatis serovars A (strain Har-13), B (strain TW-5), and C (strain TW-3) were grown in stationary cultures of HeLa 229 cells, and chlamydial elementary bodies (EBs) were purified from infected cells by density gradient centrifugation as previously described (6 Convalescent antichlamydia sera. Convalescent sera were obtained from cynomolgus monkeys that had recovered from a primary conjunctival infection with serovar A. Preimmune sera were taken prior to experimental infection, and convalescent sera were taken 45 days postinfection, approximately 2 weeks after the monkeys became culture negative and were free of any clinical signs (conjunctival hyperemia and follicles) of disease. The sera were heat inactivated at 56°C for 30 min prior to assay.
Antigens and inoculations. Rabbits were inoculated either with CsCl-purified PV1-Ct7 or PV1-XLD or with serovar A MOMP or synthetic peptide A8-VDI. Note that although the viruses used were live, poliovirus does not replicate in rabbits (22) , and any response observed is effectively the response to an inactivated antigen. The synthetic peptide A8-VDI, a 40-mer, contains VDI of serovar A MOMP, including the B-cell epitope VAGLEK, and a MOMP helper T-cell epitope (39) . MOMP was gel purified as described previously (6 14 and 28, the rabbits were each given one booster dose in Freund's incomplete adjuvant subcutaneously on the back. Blood samples were taken prior to the first inoculation and after 42 days. This protocol was based on that described previously for similar studies (1, 28, 29) .
Poliovirus plaque and neutralization assays. Plaque assays were performed as described by Emini et al. (11) . Sera were titrated for their ability to neutralize 100 50% tissue culture infectious doses of virus, using the method of Golding et al. (16) Pepscan-ELISA. The peptide-pin-based assay described by Geysen et al. (14, 15) was used to determine the fine specificity of the rabbit anti-PV1-Ct7 antisera. Sequential and overlapping octapeptides corresponding to the serovar A MOMP VDI sequence (residues 61 to 85) were synthesized on prederivatized polyethylene pins with a commercially available kit (Epitope Scanning Kit; Cambridge Research Biochemicals Inc., Wilmington, Del.) using f-moc chemistry as described by the manufacturer. Rabbit antisera diluted 1:500 were incubated with the individual peptide pins. Rabbit IgG bound to the peptides was detected by using alkaline phosphatase-conjugated goat anti-rabbit IgG antibodies, as described for ELISA.
In vitro neutralization of chlamydiae. Hamster kidney (HaK) cells (105 cells per well) were grown overnight in flat-bottomed 96-well microtiter plates (Linbro; Flow Laboratories Inc., McLean, Va.). Serovar A and C EBs were diluted in SPG (0.25 M sucrose, 10 mM sodium phosphate, 5 mM L-glutamic acid [pH 7.2]). To determine serum neutralization titers, twofold dilutions of heat-inactivated (56°C for 30 min) sera were made in SPG. One hundred microliters of diluted sera was mixed with 100 ,u of EBs in SPG at 6.6 x 105 inclusion-forming units (IFU) per ml and then incubated at 37°C for 30 min. After incubation, 50-,ul aliquots from each mixture were inoculated in triplicate onto HaK monolayers. The monolayers were incubated at 37°C for 2 h, washed once with 100 ,ul of Hanks balanced salt solution (HBSS) and then fed with 200 ,l of minimal essential medium containing 10% fetal calf serum and 1 ,ug of cycloheximide per ml. Cells were incubated at 37°C for 48 to 70 h, washed with HBSS, and fixed with absolute methanol.
To visualize chlamydial inclusions, methanol-fixed cells were incubated with a MAb to chlamydial lipopolysaccharide followed by a fluorescein-conjugated rabbit anti-mouse antibody (34) . Fluorescent chlamydial inclusions were counted in 10 microscopic fields of view at x 100 magnification from triplicate wells. In neutralization assays, the percent reduction of IFUs was calculated by comparison with preimmune serum control values.
In vivo neutralization of chlamydiae. The ability of rabbit antisera to PV1-Ct7 to passively protect in vivo was assayed by using a monkey model of chlamydial ocular infection. A 300-,ul volume of serovar A EBs in SPG (1.0 x 106 IFU) was mixed with 300 R1 of a 1:100 dilution of pooled, heatinactivated (56°C, 30 min) anti-PV1-Ct7 or preimmune sera and incubated at 37°C for 30 min. Immediately after the incubation, 20-pI portions of the serum-chlamydia mixtures were inoculated onto the upper and lower conjunctivae of both eyes of three cynomolgus monkeys.
Clinical disease developed by the monkeys was scored by evaluating hyperemia and follicle formation of the upper and lower palpebral conjunctivae of both eyes. The clinical grading scheme described by Taylor et al. (43) was used, and the data are expressed as aggregate inflammatory and follicle scores of both eyes for individual monkeys. All inoculations RNA transcripts prepared from three of five hybrid cDNAs (pT7Ct5, pT7Ct7, and pT7Ct8) were infectious in Vero cells, producing viable hybrid viruses, whereas RNA transcripts prepared from the other two hybrid cDNAs did not produce virus after two independent transfections (Fig. 1) . The three hybrids recovered were designated PV1-Ct5, PV1-Ct7, and PV1-Ct8. PV1-Ct5 grew very slowly and produced small, almost pinpoint, plaques in Vero cells. Because of its poor growth properties, it was not studied further. PV1-Ct7 and -Ct8 grew very well, producing plaques similar in size to or slightly smaller than those of PV1-XLD, respectively (data not shown). In a single-step growth cycle, both hybrids were slightly impaired compared with PV1-XLD; PV1-XLD grew faster than PV1-Ct8, which grew faster than PV1-Ct7 ( Single-step growth curves of PV1-XLD, PV1-Ct7, and PV1-Ct8. Virus was grown and recovered as described previously (29) and then titrated by plaque assay. Points represent the mean values of titrations in duplicate wells.
2). The peak titers for PV1-Ct7 and PV1-Ct8 were only 0.6 and 0.75 log1o, respectively, below the peak titer for PV1-XLD (Fig. 2) . Consequently, preparing adequate quantities of the hybrids for further study was not a problem.
Antigenic characteristics of hybrid polioviruses. The antigenic characteristics of PV1-Ct7 and -Ct8 are shown in Table  1 . Both were neutralized by MAb A-20, which is specific for the VAGLEK neutralization epitope from VDI of serovar A MOMP, indicating that this epitope is expressed in a recognizable and antigenic form on both hybrids. The higher titer against PV1-Ct7 suggests that this hybrid expresses the VAGLEK epitope in an antigenic configuration closer to that of the native epitope on intact chlamydiae. Significantly, the hybrids were also neutralized by convalescent sera from infected primates, indicating that the chlamydial sequence was expressed in a form recognizable during a natural infection. Although the titers in this case were low, it should be noted that the chlamydial infection generated only a weak humoral immune response and that the chlamydia-neutralizing titers of these sera were also low.
The hybrids induced a strong antipoliovirus response and were neutralizable by antipoliovirus (PV1-XLD) antisera, indicating that the changes to poliovirus NAgI had not significantly affected other antigenic sites on the virus. Since PV1-Ct7 was more readily neutralizable by MAb A-20, which suggested that it may express the VAGLEK epitope in a more appropriate conformation, this hybrid was selected for further study.
Immunogenicity of hybrid poliovirus. (i) Immunoblotting. The sera from rabbits immunized with PV1-Ct7 and PV1-XLD were tested by Western blotting against C. trachomatis serovars A, B, and C to determine the specificity of the anti-MOMP response. These analyses showed that all four rabbit antiserum samples raised against PV1-Ct7 reacted very strongly with the homotypic serovar A MOMP (Fig. 3) . Moderate cross-reactivity against the heterologous serovar C MOMP was observed with one serum sample (rabbit 13), but the other three serum samples were not immunoreactive with serovar C MOMP. None of the anti-PV1-Ct7 antisera recognized serovar B MOMP. Sera raised against PV1-XLD did not react with the MOMPs of any of the three C. trachomatis serovars. These results show that PV1-Ct7 is capable of eliciting a consistent antibody response to serovar A MOMP and that the response is specific for the VDI sequence encoded by this hybrid.
(ii) Fine specificity of anti-PV1-Ct7 antisera. The sera from rabbits immunized with PV1-Ct7 were analyzed by pepscan-ELISA against overlapping octapeptides corresponding to the serovar A MOMP VDI sequence to ascertain the fine specificity of the anti-PV1-Ct7 response. The sera from all four rabbits showed a marked immunoreactivity with VDI octapeptides containing the VAGLEK sequence (Fig. 4) . This result shows that PV1-Ct7 is capable of eliciting a consistent antibody response specific for the serovar A MOMP VDI sequence and, in particular, for the targeted VAGLEK epitope.
(iii) ELISA. The specificities and antibody titers of the anti-PV1-Ct7 sera were further tested by ELISA and compared with rabbit antisera raised against either purified serovar A MOMP or peptide A8-VDI ( Table 2 ). The sera were tested against peptide A-VDI, which corresponds to serovar A residues 61 to 85 and contains the VAGLEK epitope, and formalin-fixed serovar A, B, and C EBs. Rabbit antisera raised against the control virus, PV1-XLD, did not react with any of the chlamydial antigens at the highest concentration of sera tested (1:32). All four rabbits immunized with PV1-Ct7 produced high-titer antisera (8, 192 MOMP on the chlamydial surface. Anti-PV1-Ct7 sera also exhibited considerable cross-reactivity against serovar C by ELISA. However, unlike the responses against serovar A, the responses against serovar C were clearly more variable among immunized rabbits, with titers ranging from 256 to 8, 192 . None of the anti PV1-Ct7 sera reacted in ELISAs with serovar B at a dilution of 1:32. The observed cross-reactivity between serovars A and C is not particularly surprising, since the primary sequences of their VDIs are very similar. Antiserum from rabbit 13 had an equivalent ELISA endpoint titer (8, 192 ) against both serovar A and C EBs, which is inconsistent with the Western blot results shown in Fig. 3 . The reason for this inconsistency is not understood, but it may reflect differences in antibody avidity or specificity for denatured and native forms of the MOMP.
In contrast to these results, rabbits inoculated with doses of purified serovar A MOMP or A8-VDI that contained the same molar amount of the VAGLEK epitope as in the dosage of PV1-Ct7 produced markedly lower and more variable antibody responses against both peptide A-VDI and serovar A EBs. These doses of purified MOMP and A8-VDI were significantly less (100-to 200-fold) than those we have previously found to induce antibody responses comparable in titer and specificity to those induced here by PV1-Ct7 (39) . Nevertheless, these findings clearly demonstrate the superior immunogenicity of PV1-Ct7 in its ability to induce serovar A-specific antibodies.
In vitro neutralization of chlamydial infectivity by anti-PVlCt7 antisera. The rabbit anti-PV1-Ct7 antisera were tested for their ability to neutralize chlamydial infectivity for HaK cells. The results were consistent with those obtained by ELISA. All four serum samples exhibited consistent hightiter neutralizing activity against the homotypic serovar A (Fig. 5) , in that for each serum sample, the dilution which caused a 50% reduction in serovar A infectivity was approximately 1:2,048. These sera also showed neutralizing activity against serovar C. However, except for sera from rabbit 13 (which caused a 50% reduction in serovar C infectivity at a dilution of approximately 1:2,048), the anti-serovar C neutralizing titers were lower and more variable than the antiserovar A titers.
Passive in vivo neutralization of chlamydial infectivity for the monkey eye by anti-PV1-Ct7 antisera. The ability of rabbit anti-PV1-Ct7 antisera to neutralize chlamydial infectivity for HaK cells was a significant finding. However, it was important to determine whether the anti-PV1-Ct7 sera were capable of neutralizing chlamydial infectivity for cells which are more typically colonized by chlamydiae in the context of a naturally occurring ocular infection. We therefore tested the ability of rabbit anti-PV1-Ct7 sera to passively neutralize the infectivity of serovar A EBs for the conjunctivae of cynomolgus monkeys, an animal model that closely resembles human chlamydial ocular infection. As shown in Table 3 , anti-PV1-Ct7 antisera were passively neutralizing in this context. All three monkeys inoculated with chlamydiae incubated with preimmune sera shed chlamydiae from their conjunctivae at 7, 14, and 21 days postchallenge. These monkeys also developed a mild follicular conjunctivitis characterized by conjunctival hyperemia and follicle formation. In contrast, those monkeys that received chlamydiae incubated with anti-PV1-Ct7 antisera were culture negative through day 21 postchallenge, and none developed clinical signs of conjunctivitis.
DISCUSSION
We have constructed and characterized two viable hybrid polioviruses (PV1-Ct7 and -Ct8) in which part of NAgI, the BC loop of VP1, has been replaced by sequences specific to VDI of the MOMP of C. trachomatis serovar A, including the well-characterized VAGLEK neutralization epitope. These hybrids were found to be only slightly growth impaired compared with their wild-type parent and grew better than many other previously described hybrids (see, for example, references 26 and 27). A third poliovirus-chlamydia hybrid (PV1-Ct5) grew poorly, and two other hybrids were apparently not viable. While we cannot rule out the effect of second-site mutations, it appears that the hybrids which grew best were those which retained some of the poliovirus VP1 BC loop amino acids on either side of the inserted sequence, particularly on the amino-terminal side. Conversely, those hybrids which grew poorly were those in which these amino acids had been deleted to keep the BC loop closer to its natural length. This result suggests that the sequence of the VP1 BC loop is more important than its length in determining the viability of poliovirus hybrids, which is consistent with our earlier observations (26, 27) .
PV1-Ct7 and -Ct8 clearly express at least one C. trachomatis-specific epitope in a recognizable conformation which is presumably similar to that of the native epitope(s). The hybrids were neutralized both by MAb A-20, specific for the VAGLEK epitope of serovar A MOMP VDI, and by monkey convalescent sera. Rabbit antisera raised against PV1-Ct7 were strongly immunoreactive with octapeptides containing the sequence VAGLEK. The same antisera neutralized the infectivity of serovar A EBs both in vitro and, more significantly, in vivo. Thus, the expressed epitope(s) were both recognized by and induced antibodies which were functionally relevant, including antibodies which were neutralizing in an appropriate animal model. Furthermore, PV1-Ct7 is a potent immunogen, consistently able to induce high titers of antichlamydia neutralizing antibodies. PV1-Ct7 was substantially more immunogenic, on an equimolar basis, than either purified A MOMP or synthetic peptide A8-VDI. Purified MOMP and peptide A8-VDI have been proposed as potential antigenic components of a chlamydial vaccine (6, 9, 39, 47) , and thus it is of particular interest that a poliovirus-chlamydia hybrid is so powerfully immunogenic in comparison. There are several possible explanations for the superior immunogenicity of the hybrid. One possibility is that poliovirus Th epitopes provide a better carrier effect by supplying cognate help to prime for a strong anamnestic response to successive doses of the hybrid. Another possibility is that the chlamydial epitopes expressed in the BC loop of VP1 are presented in a conformation that structurally mimics that of the epitopes on native MOMP, resulting in greater immunogenicity and the induction of antibodies with enhanced affinity for native MOMP. The second possibility would be consistent with earlier suggestions that the immunogenicity of isolated MOMP might be enhanced under conditions which maintain its native conformation (3).
We did not raise antisera to intact chlamydial EBs in this study, since they could probably not be included in any potential chlamydial vaccine. However, in other similar studies (5a), we have observed that doses of serovar A EBs containing approximately 50 nmol of the VAGLEK epitope induced serovar A-specific antibody titers, comparable to those induced by the hybrids (30 pmol of the epitope) in this study. This result also suggests that the VAGLEK epitope and other VDI epitopes which may be present are presented at least as well on the poliovirus hybrids as they are on intact EBs.
Rabbits inoculated with PV1-Ct7 produced considerable cross-reactivity against serovar C EBs (Table 2 ). This result is not unexpected, considering that the VDIs of serovar A and C MOMP have very similar primary sequences (49) . The region of serovar A VDI encoded by PV1-Ct7 is TTSDVA GLEKDPVA (Fig. 1) ; the equivalent sequence from serovar C, TTSDVAGLQNDPI, differs by only four amino acids (underlined). Thus, a polyclonal antibody response generated against the serovar A sequence should elicit not only antibodies against the VAGLEK epitope but also antibodies against shared sequences that would correspond to antigenic determinants common to both these two closely related serovars. This cross-reactivity is very attractive in terms of providing a broader neutralizing response against multiple serovars, but the anti-serovar C reactivity generated by PV1-Ct7 was much more variable among rabbits than the anti-serovar A reactivity (Table 2 optimizing the expressed chlamydial sequence. For instance, we have found that sera from rabbits inoculated with PV1-Ct7 or PV1-Ct8 cross-react with several chlamydial serovars of the C complex in Western blot assays against MOMP and dot blot assays against intact chlamydiae and that some rabbits mount a response of approximately equal strength against at least four C-complex serovars (A, C, I, and J) (data not shown). It would be interesting to determine the epitope(s) recognized by these animals, since this might Serum dilution (reciprocal) FIG. 5 . Neutralization of C. trachomatis serovars A and C by anti-PV1-Ct7 antisera from rabbits 13 to 16 (R13 to R16, respectively). Pooled anti-PV1-XLD antisera were nonneutralizing (not shown). Neutralization assays were conducted as described in Materials and Methods. allow us to define a sequence which could reproducibly generate a strong C-complex cross-reactive response. Furthermore, the approach that we have used to construct a poliovirus-serovar A hybrid should be directly applicable to other chlamydial serovars. The sequence of serovar C VDI is very similar to that of serovar A VDI and should be readily expressible on a poliovirus-serovar C hybrid. On the basis of our findings with PV1-Ct7, a poliovirus-serovar C hybrid would be expected to be highly immunogenic, and importantly, it should induce a consistent anti-serovar C neutralizing antibody response.
It has been proposed that poliovirus hybrids expressing heterologous epitopes could be used as vaccines (5, 29) , although, to our knowledge, no such vaccines have yet been developed. The The studies described here were undertaken to demonstrate the feasibility of constructing immunogenic polioviruschlamydia hybrids, and immunogenicity was assessed in terms of a humoral immune response in rabbits. Obviously it is important to examine the role of mucosal immunity in chlamydial infection, and poliovirus-chlamydia hybrids have the potential to be a powerful tool. Poliovirus infection is known to induce a strong mucosal antibody response following gut infection (12, 13, 31) , and the common nature of the mucosal immune system means that this response should extend to the mucosal surfaces at risk of chlamydial infection, those of the conjunctivae and genital tract. Exposure of gut-associated lymphoid tissue to antigen ultimately results in the dispersal of antigen-sensitized immunoblasts to mucosal surfaces throughout the body, where they can initiate synthesis of antigen-specific secretory IgA (4, 31) . Since cynomolgus monkeys have a long history of use as models for both poliovirus (35, 48) and chlamydial (41, 43) infections, it should be feasible to evaluate the immunogenicity and protective efficacy of orally administered attenuated poliovirus-chlamydia hybrids in a primate model of chlamydial disease. Such studies should allow us to demonstrate conclusively whether a strong mucosal immune response is in fact protective against chlamydial infection, which would be a valuable contribution to the development of a chlamydial vaccine.
